Emerging Therapies in Castrate-Resistant Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Emerging therapies in castrate-resistant prostate cancer.
Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecul...
متن کاملCurrent management of castrate-resistant prostate cancer.
Prostate cancer (PCa) is the most frequently diagnosed cancer in North America. Castrate-resistant PCa presents a spectrum of disease ranging from rising PSA levels in the absence of metastases or symptoms and despite androgen-deprivation therapy, to metastases and significant debilitation from cancer symptoms. Castrate-resistant PCa is usually suspected in patients with new symptoms on androge...
متن کاملEmerging Targeted Therapies for Castration-Resistant Prostate Cancer
Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this setting, and to-date several other agents are under investigation in clinical trials. The purpose of this review is to present an update ...
متن کاملDevelopment of Novel Secondary Hormonal Therapies for Castrate-Resistant Prostate Cancer
Androgen deprivation therapy (ADT), initially via surgical orchiectomy and more contemporarily with medical castration through the use of luteinizing hormone-releasing hormone (LHRH) agonists, has been the mainstay of treatment for advanced prostate cancer for more than 60 years (Huggins and Hodges, 1941). Though initially effective in decreasing serum PSA, lessening pain from bone metastases, ...
متن کاملNovel non-AR therapeutic targets in castrate resistant prostate cancer
Castrate resistant prostate cancer (CRPC) remains a disease with significant morbidity and mortality. The recent approval of abiraterone and enzalutamide highlight the improvements which can be made targeting the androgen receptor (AR) axis. Nonetheless, resistance inevitably develops and there is continued interest in targeting alternate pathways which cause disease resistance and progression....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Urology Reports
سال: 2010
ISSN: 1527-2737,1534-6285
DOI: 10.1007/s11934-010-0104-x